These studies collectively suggest that miR-195 acts as a significant molecular brake in LSCC pathogenesis, with its downregulation linked to enhanced tumor aggressiveness, offering a potential therapeutic angle targeting the miR-195/ROCK1 and miR-195/circMYLK/cyclin D1 axes to curb LSCC progression. Here, CCND1 is linked to neoplasm.